Are the goals of psoriasis treatment achievable in real clinical practice?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Severe forms of psoriasis are very often associated with comorbid pathology. At the same time, comorbid pathology aggravates the course of psoriasis and reduces the effectiveness of therapy, in particular, with disease-modifying and biological drugs. In many patients with comorbid pathology, only biological therapy drugs can be used as therapy for severe psoriasis due to relative contraindications for other drugs for systemic therapy of psoriasis. Psoriatic patients with comorbid pathology should be managed by dermatologists and related specialists: endocrinologists, cardiologists, nutritionists, physiotherapy specialists to correct conditions that worsen the course of psoriasis and negatively affect the therapeutic effect of systemic drugs. The drug guselkumab is actively introduced into the practice of dermatovenerologists for the treatment of moderate and severe psoriasis. The presented clinical cases demonstrate the high efficacy of guselkumab in patients with comorbid pathology, as well as in achieving PASI90 and PAS1100 in patients with severe psoriasis. The treatment was well tolerated; no adverse events were found during therapy. The data of clinical studies and practical experience of use determine the choice of guselkumab as a drug with the best efficacy profile for the current period, a stable safety profile and the possibility of using in patients with combined comorbid pathology.

Full Text

Restricted Access

About the authors

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
Dr. Sci (Med.), Professor, Vice-Rector for Academic Affairs, Head of the Department of Dermatovenereology and Cosmetology

A. A Khotko

Clinical Dermatovenerologic Dispensary, Krasnodar

N. S Rudneva

Tula Regional Clinical Dermatovenerologic Dispensary

References

  1. Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М., 2014. 264 с.
  2. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-71. doi: 10.1016/S0140-6736(07)61128-3.
  3. Johnson-Huang L.M., Lowes M.A., Krueger J.G. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech. 2012;5:423-33. doi: 10.1242/dmm.009092.
  4. Carrascosa J.M. Immunogenicity in biologic therapy: implications for dermatology Actas Dermosifiliogr. 2013;104:471-79. Doi: 10.1016/j. ad.2013.02.005.
  5. Girolomoni G., Griffiths C., Krueger J., et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. J. Dermatol Treat. 2014;26(2):103-12. doi: 10.3109/09546634.2014.880396.
  6. Langan S.M., Seminara N.M., Shin D.B., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J. Invest Dermatol. 2012;132:556-62. doi: 10.1038/jid.2011.365.
  7. Guenther L., Gulliver W. Psoriasis comorbidities. J. Cutan Med Surg. 2009;13(Suppl 2):77-87. doi: 10.2310/7750.2009.00024.
  8. Boehncke W.H., Boehncke S. Research in practice: the systemic aspects of psoriasis. J. Dtsch Dermatol Ges. 2008;6(8):622-25. doi: 10.1111/j.1610-0387.2008.06785.x.
  9. Росет-Пидаль Е.А., Круглова Л.С., Понич Е.С. и др. Терапия больных псориазом с сопутствующим метаболическим синдромом препаратами биологической терапии: предикторы эффективности и потенциальные риски. Медицина труда и промышленная экология. 2017;8:33-8.
  10. Kacalak-Rzepka A., Kiedrowicz M., Maleszka R. Analysis of the chosen parameters of metabolic status in patients with psoriasis. Ann Acad Med Stetin. 2013;59(2):12-7.
  11. Бутрова С.А., Дзгоева Ф.Х. Висцеральное ожирение - ключевое звено метаболического синдрома. Ожирение и метаболизм. 2004;1:10-6.
  12. Takeshtta J., Grewal S., Langan S.M., et al. Psoriasis and comorbid diseases: epidemiology. J. Am Acad Dermatol. 2017;76:377-90. Doi: 10.1016/j. jaad.2016.07.064.
  13. Соколовский Е.В., Круглова Л.С., Понич Е.С. «Болевые» точки системной терапии биологическими препаратами при псориазе. Российский журнал кожных и венерических болезней. 2015;18(6):32-38.
  14. Круглова Л.С., Моисеев С.В. Блокада интерлейкина 17 - новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017;26(2):5-12.
  15. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;12(3):4-18.
  16. Клинические рекомендации. Псориаз. 2020. URL' http://cr.rosminzdrav.ru/#!/schema/866 (дата обращения: 23.07.2020).
  17. Rasmussen M.K. The Importance of Achieving Clear or Almost Clear Skin for Patients: Results from the Nordic Countries of the Global. Acta Derm Venereol. 2019;99(2):158-63. Doi: 10.2340/ 00015555-3048.
  18. Хотко А.А., Помазанова М.Ю., Круглова Л.С. Таргетная терапия псориаза: ингибирование сигнального пути ИЛ-23 - данные клинических исследований и реальной практики. Вестник дерматологии и венерологии. 2020;96(4):49-59.
  19. Круглова Л.С., Львов А.Н., Пушкина А.В. Риски и предикторы псориатического артрита при псориазе и вопросы раннего назначения генно-инженерных биологических препаратов. Клиническая дерматология и косметология. 2020;19(3):289-296.
  20. Armstrong A.W., Puig L., Joshi A., et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156(3):258 69. doi: 10.1001/jamadermatol.2019.4029
  21. Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019;15(6):589-97. doi: 10.1080/1744666X.2019.1601014
  22. Тремфея (гуселькумаб). Инструкция по медицинскому применению препарата ЛП-005686 от 28.05.2020
  23. Langley R.G., Tsai T.F., Flavin S., et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J. Dermatol. 2018;178(1):114-23. Doi: 10.1111/ bjd.15750.
  24. Langley R., Blauvelt A., Armstrong A., Li M.C.H. Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to severe psoriasis: Results from the ECLIPSE trial. The 3rd Inflammatory Skin Disease Summit, Vienna, Austria, 12.12.2018-15.12.2018.
  25. Blauvelt A., Papp K.A., Griffiths C.E.M., et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J. Am Acad Dermatol. 2017;76(3):405-17. Doi: 10.1016/j. jaad.2016.11.041.
  26. Reich K., Armstrong A.W., Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418-31. doi: 10.1016/j.jaad.2016.11.042
  27. Langley R.G.B., et al. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J. Dermatol Treat. 2015:26(1):23-31. doi: 10.3109/09546634.2013.865009.
  28. Griffiths C.E.M., Fall Clinical Dermatology Conference; October 17-20, 2019. Las Vegas, NV URL:www. mhra.gov.uk/yellowcard
  29. Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin. Immunol. 2019;15(6):589-97. doi: 10.1080/1744666X.2019.1601014.
  30. Gordon K.B., Armstrong A.W., Foley P., et al. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J. Invest Dermatol. 2019;139(12):2437-46.e1. Doi: 10.1016/j. jid.2019.05.016.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies